Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-44,347
Closed -$2.96M 67
2024
Q3
$2.96M Buy
44,347
+25,484
+135% +$2.34M 0.75% 39
2024
Q2
$2.24M Sell
18,863
-13,325
-41% -$1.69M 0.61% 45
2024
Q1
$3.43M Hold
32,188
0.89% 35
2023
Q4
$3.2M Hold
32,188
0.63% 51
2023
Q3
$3.25M Buy
32,188
+3,052
+10% +$340K 0.69% 48
2023
Q2
$3.57M Buy
29,136
+12,727
+78% +$1.7M 0.73% 47
2023
Q1
$2.42M Buy
+16,409
New +$2.71M 0.55% 60

Other funds holding MRNA

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's MRNA Position: Q4 2024 in Review

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet sold out of Moderna (MRNA) in Q4 2024, closing a stake of 44,347 shares — an estimated $2.96M sold.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet first reported a position in MRNA in Q1 2023 and held it in 7 quarters. The position peaked at $3.57M in Q2 2023. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet sold 44,347 Moderna shares in Q4 2024, an estimated $2.96M.
  • Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet first reported a position in Moderna in Q1 2023 and held it in 7 quarters.
  • Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's Moderna position peaked at $3.57M in Q2 2023.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet's 13F filing for Q4 2024, filed 10 Feb 2025.